Plicamycin

Summary

Plicamycin (CHEMBL1237054) is an approved small molecule (ATC L01DC02); indicated across 3 conditions including neoplasm and ewing sarcoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01DC02
• Indications: 3 conditions
• Clinical trials: 3
• Chemistry: 1085.1 Da · C52H76O24

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1237054
Name	Plicamycin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	52945526
ATC	L01DC02
Molecular formula	C52H76O24
Molecular weight	1085.1
InChIKey	XDKMHMINQXATOR-RCFLUEAHSA-N

SMILES: C[C@@H]1[C@H]([C@@H](C[C@H](O1)O[C@@H]2C[C@@H](O[C@@H]([C@H]2O)C)OC3=CC4=CC5=C(C(=O)[C@H]([C@@H](C5)[C@@H](C(=O)[C@H]([C@@H](C)O)O)OC)O[C@H]6C[C@H]([C@@H]([C@H](O6)C)O)O[C@@H]7C[C@H]([C@H]([C@H](O7)C)O[C@@H]8C[C@]([C@@H]([C@H](O8)C)O)(C)O)O)C(=C4C(=C3C)O)O)O)O

IUPAC name: (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2R,4R,5R,6R)-5-[(2R,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5R,6R)-4-[(2R,4R,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-8,9-dihydroxy-7-methyl-3,4-dihydro-2H-anthracen-1-one

Also known as: A-2371, ANTIBIOTIC LA-7017, Aureolic acid, LA-7017, Mithracin, Mithramycin, Mithramycin a, NSC-24559, PA-144, Plicamicina, Plicamycin, Plicamycine

Patent coverage: 405 distinct patent families (778 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q9R1A7	6.5	EC50	320	nM	CHEMBL_ACT_15463838

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
Ewing sarcoma	1	MONDO:0012817	EFO:0000174
sarcoma	1	MONDO:0005089	EFO:0000691

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01610570	PHASE1/PHASE2	TERMINATED	Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma
NCT01624090	PHASE2	TERMINATED	Mithramycin for Lung, Esophagus, and Other Chest Cancers
NCT02859415	PHASE1/PHASE2	TERMINATED	Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).